JPRN-UMIN000004124招募中1 期
Phase1 trial of Cetuximab/S-1 combination therapy for Advanced/Recurrent Colorectal Cancer - Phase1 trial of Cetuximab/S-1 combination therapy for Advanced/Recurrent Colorectal Cancer
Kinki university school of medicine Department of clinical oncology0 个研究点目标入组 21 人开始时间: 2010年8月30日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)A case with the interstitial pneumonia that is clear by chest CT or pulmonary fibrosis. (2)A case receiving flucytosine (a pyrimidine system antifungal agent fluoride). (3)A case with a history of serious drug allergy. (4)The case with pleural effusion, ascitic fluid needing treatment such as the drainage and the pericardial fluid. (5) The case with serious heart disorder, myocardial infarction within six months, hypertension having poor control, bacterial infection and fungal infection of the activity and other serious complications (haemorrhage of digestive tract). (6)A case to have a short bowel syndrome merger or diarrhea (watery feces) continuously. (7) Intestinal paralysis, a case with bowel obstruction. (8) Metastases to brain case with the symptom.A case (as for the metastases to brain case that a symptom was stable by metastases to brain case and radiotherapy and medical treatment without the symptom, possible registration) to need the antihydropic including the steroid of the symptom control purpose. (9)A case with the diabetes mellitus inadequate control. (10)The case that it was judged mental disorder to become the clinical problem to have difficulty in registration to this study. (11)A case to have pregnant or pregnant possibilities, the case that there is not of the intention to prevent conception and the case that we are nursing. (12)In addition, the case that we judged to be inadequate though the medical attendants conducted this study
研究者
相似试验
招募中
不适用
Phase I trial of Cetuximab combined with S-1 and irrinotecan in advanced colorectal cancercolorectal cancerJPRN-UMIN000003703Toho University school of Medicine10
已完成
2 期
Phase II trial of S-1 plus Cetuximab combination chemotherapy for advanced recurrent/metastatic carcinoma of the oral cavityAdvanced recurrent/metastatic carcinoma of the oral cavityJPRN-UMIN000024371Osaka University20
已完成
2 期
Phase II trial of S-1 plus Cetuximab combination therapy in patients inappropriate for platinum-based therapy with recurrent/metastatic squamous cell carcinoma of the head and neckJPRN-UMIN000015123Hokkaido University21
招募中
1 期
Phase I/II study of Cetuximab combined with S-1 and irrinotecan (CeIRIS) in KRAS wild type metastatic colorectal cancer patients refractory to treatment with oxaliplatin and fluoropyrimidine.Colorectal cancer: KRAS wild typeJPRN-UMIN000003288Kyushu Medical Oncology Group40
尚未招募
1 期
Phase I/II trial of S-1+Nedaplatin+Cetuximab for recurrent/metastatic head and neck squamous cell carcinomahead and neck squamous cell carcinomaJPRN-UMIN000012074Kyorin University School of Medicine, Department of Otolaryngology30
